Clinical Trials Directory

Trials / Completed

CompletedNCT00629733

Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of a New Ultra Low Molecular Weight Heparin (RO-14) Administered Subcutaneously Increasing Single-doses to Healthy Male Volunteers

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
12 (estimated)
Sponsor
Rovi Pharmaceuticals Laboratories · Industry
Sex
Male
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

Clinical trial to evaluate the tolerability and pharmacokinetics of a new ultra low molecular weight heparin (RO-14) administered subcutaneously increasing single-doses to healthy male volunteers

Conditions

Interventions

TypeNameDescription
DRUGRO-14

Timeline

Start date
2007-12-01
Primary completion
2007-12-01
Completion
2008-12-01
First posted
2008-03-06
Last updated
2011-06-08

Locations

1 site across 1 country: Spain

Source: ClinicalTrials.gov record NCT00629733. Inclusion in this directory is not an endorsement.